IndustryCompany release

Pelthos Q3 Zelsuvmi revenue rises 114% to $15.2M as Castle Creek merger nears

🇺🇸 Pelthos Therapeutics Inc. (PTHS) · Thu 12 Nov 2026

Pelthos Therapeutics reports third-quarter Zelsuvmi sales of $15.2M, wider commercial coverage, an enlarged Horizon loan and an expected Q1 2027 close for its Castle Creek deal.

Pelthos Therapeutics reported third-quarter 2026 results on 12 November, with net revenue from its dermatology product Zelsuvmi reaching $15.2M, a 114% increase.

Commercial formulary coverage for Zelsuvmi has risen to 127 million lives, according to the company. The update gives no further detail on which payers or plans account for the increase.

Pelthos also set out its pending merger with Castle Creek Biosciences. Castle Creek's lead asset is D-Fi, a gene-modified cell therapy aimed at dystrophic epidermolysis bullosa. Pelthos expects the merger to close by the end of the first quarter of 2027.

On financing, Pelthos amended its loan with Horizon Technology Finance to provide up to $50M. The company drew an additional $10M under the amended facility on 30 October.

What it means for your team

  • Market-access teams may note that Zelsuvmi's commercial formulary coverage has grown to 127 million lives, a figure Pelthos presents as supporting its sales growth.
  • The planned Castle Creek merger would add a gene-modified cell therapy for dystrophic epidermolysis bullosa to Pelthos's dermatology portfolio, if it closes as expected by the end of Q1 2027.
  • Regulatory and quality teams tracking advanced therapies in rare skin disease should watch for post-merger updates on D-Fi.

Company's press release (SEC filing): Pelthos Therapeutics Inc. ↗

Article written by VigiEye from the official source (Pelthos Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →